Medtronic PLC (NYSE: MDT) is a medical device company that develops, manufactures, and sells implantable and interventional therapies across cardiovascular, neuromodulation, spine, surgical, and acute care markets. Revenue comes from transactional product sales to hospitals, ambulatory care centers, physicians' offices, and other healthcare providers globally. Medtronic operates through segments that include cardiac rhythm management, cardiac ablation, neuromodulation, surgical and endoscopy, and acute care and monitoring. Key products include implantable cardiac defibrillators and resynchronization devices under the Claria, Cobalt, and Crome brands, pulsed field and cryoablation catheters for arrhythmia treatment, the SynchroMed III implantable drug infusion system, the Kyphon vertebral compression fracture portfolio, and the Reveal LINQ insertable cardiac monitor. For fiscal year ended April 25, 2025, GAAP net income attributable to Medtronic was $4.662 billion on diluted EPS of $3.61. The company is incorporated in Ireland and operates worldwide, with reimbursement from government programs including Medicare, Medicaid, and volume-based procurement tenders in China affecting pricing across its product lines.

Revenue model

Transactional product sales of implantable devices, capital equipment, disposables, and consumables to hospitals, ambulatory care centers, and physicians. Reimbursement levels set by Medicare, Medicaid, private insurers, and national tender programs in markets including China directly influence realized selling prices.

Products and services

Cardiac rhythm devices: Claria, Amplia, Compia CRT-D/CRT-P families; Cobalt and Crome BlueSync CRT-Ds; Arctic Front Advanced Cardiac Cryoablation System; PulseSelect Pulsed Field Ablation catheter; Sphere-9 focal catheter; Affera Mapping and Navigation System with Prism-1 software; Reveal LINQ and LINQ II insertable cardiac monitors. Neuromodulation: SynchroMed III Implantable Infusion System. Spine and interventional: Kyphon Kyphoplasty and Vertebroplasty portfolio; OsteoCool cooled radiofrequency ablation system; Emprint Microwave with Thermosphere technology; Accurian nerve ablation system. Medical Surgical Portfolio covering Surgical and Endoscopy and Acute Care and Monitoring divisions.

Customers and end markets

Primary customers are hospitals and healthcare systems, physicians' offices, ambulatory care centers, and alternate-site healthcare providers. End markets include cardiac arrhythmia management, heart failure, chronic and cancer pain, spasticity, vertebral compression fractures, metastatic bone lesions, liver tumors, and general surgical and acute care settings. Government payers including Medicare and Medicaid, private insurers, and managed-care plans are the indirect economic buyers that set reimbursement rates.

Value-chain role

Vertically integrated medical device manufacturer. Medtronic holds patents, trademarks, trade secrets, and other IP covering its implantable and interventional products. It manufactures proprietary devices, obtains regulatory approvals, and sells directly into healthcare settings. The company is simultaneously plaintiff and defendant in ongoing intellectual property litigation, reflecting the IP-intensive nature of its competitive position.

Geographic exposure

Worldwide operations subject to laws and regulations across multiple jurisdictions. Specific revenue by geography is not detailed in the provided filing excerpts. The filing references the U.S., China (volume-based procurement tenders), and other international markets as material operating geographies.

Source: SEC 10-K, filed 2025-06-20

Industry: Electromedical & Electrotherapeutic Apparatus Peers: STERIS plc Trinity Biotech PLC